



Hana Biosciences CEO Mark Ahn to Present at 2004 BIO Emerging Company Investor Forum

South San Francisco (October 12, 2004) – Hana Biosciences, Inc. a biopharmaceutical company headquartered in South San Francisco, California, announced today Mark Ahn, Ph.D. President and Chief Executive Officer will be presenting at the Bio Emerging Investor Forum on October 13, 2004, at 10:50AM PT. The presentation will be held at the Sea Cliff Conference Room at the Palace Hotel in San Francisco, CA. Dr. Ahn will provide a review of recent corporate developments.

About Hana Biosciences

Hana Biosciences acquires, develops, and commercializes innovative products for the treatment of important unmet medical needs in cancer and immunological diseases. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hana Biosciences can be found at www.hanabiosciences.com.

This press release contains forward-looking statements that involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana's development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Hana's product candidates, the risk that the results of clinical trials may not support Hana's claims, Hana's reliance on third party researchers to develop its product candidates and its lack of experience in developing pharmaceutical products. Additional risks are described in the company's Form 8-K filed with the Securities and Exchange Commission. Hana assumes no obligation to update these forward-looking statements, except as required by law.

Company Contact:

John Iparraguirre
e-mail: john.iparraguirre@hanabiosciences.com
(650) 588-6377

Media Contact:

Jon Weisberg
e-mail: jonweisberg@inkandair.com
(435) 658-0910

Investor Contact:

Ritu Baral
e-mail: rbaral@troutgroup.com
(212) 477-9007 ext. 25